PRACTITIONER DUE DILIGENCE: REAL-WORLD LUMACAFTOR/IVACAFTOR USE

被引：0
|
作者：
Middleton, E. A. [1 ]
McCoy, K. S. [2 ]
Novak, K. J. [1 ]
Gemma, S. [2 ]
Pape, C. [2 ]
Rice, A. [2 ]
Sakellaris, K. T. [2 ]
Kotha, K. [2 ]
机构：
[1] Nationwide Childrens, Pharm, Columbus, OH USA
[2] Nationwide Childrens, Pulm, Columbus, OH USA
来源：
PEDIATRIC PULMONOLOGY | 2017年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
269
引用
收藏
页码：S315 / S316
页数：2
相关论文
共 50 条
  • [1] REAL-WORLD TRENDS IN LONG-TERM CLINICAL OUTCOMES OF LUMACAFTOR/IVACAFTOR TREATMENT
    Muilwijk, D.
    Zomer, D.
    Gulmans, V
    van der Ent, K.
    [J]. PEDIATRIC PULMONOLOGY, 2020, 55 : S99 - S99
  • [2] LUMACAFTOR/IVACAFTOR: REAL WORLD EXPERIENCE IN A CF CENTER
    Anstead, M.
    Tupayachi, G.
    Murphy, D.
    Autry, E.
    Bulkley, V
    Kuhn, R.
    [J]. PEDIATRIC PULMONOLOGY, 2016, 51 : 302 - 302
  • [3] Variation in Use of Lumacaftor/Ivacaftor
    Hohmann, S.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [4] Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis
    Reix, Philippe
    Tatopoulos, Aurelie
    Ioan, Iulia
    Le Bourgeois, Muriel
    Bui, Stephanie
    Choukroun, Marie Luce
    Bessaci-Kabouya, Katia
    Gerardin, Michele
    Bokov, Plamen
    Da Silva, Jennifer
    Paillasseur, Jean-Louis
    Burgel, Pierre Regis
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (01) : 155 - 159
  • [5] Real-world study finds higher discontinuation rates for lumacaftor-ivacaftor than previously reported
    Clough, Isobel
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2019, 80 (11) : 634 - 634
  • [6] Sustained 12 month effectiveness with CFTRmodulator (Ivacaftor/Lumacaftor). ROCK (Real-world Orkambi CorK) study results
    Arooj, P.
    Morrissy, D.
    Ronan, N. J.
    McCarthy, Y.
    Daly, M.
    Flanagan, E.
    Shortt, C.
    McCarthy, M.
    Fleming, C.
    Eustace, J. A.
    Murphy, D. M.
    Plant, B. J.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2019, 188 (SUPPL 10) : 305 - 305
  • [7] REAL WORLD EXPERIENCE OF LUMACAFTOR-IVACAFTOR AT AN URBAN CYSTIC FIBROSIS CENTER
    Ahmad, D.
    Patel, M.
    Mills, N.
    Stephen, M. J.
    [J]. PEDIATRIC PULMONOLOGY, 2016, 51 : 205 - 205
  • [8] "REAL WORLD" IMPACT OF CFTR MODULATORS (LUMACAFTOR/IVACAFTOR AND TEZACAFTOR/IVACAFTOR) ON LONG-TERM PATIENT OUTCOMES
    Mermis, J.
    Polineni, D.
    He, J.
    [J]. PEDIATRIC PULMONOLOGY, 2019, 54 : S350 - S351
  • [9] Real World Assessment of Patients with Cystic Fibrosis Treated with Lumacaftor-Ivacaftor and Transitioned to Tezacaftor-Ivacaftor
    Christmas, A.
    O'Hagan, A. R.
    Morton, R. L.
    Eid, N. S.
    Bickel, S. G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [10] Real-World Use of Ivacaftor in Canada: A Retrospective Analysis Using the Canadian Cystic Fibrosis Registry
    Kawala, C.
    Ma, X.
    Sykes, J.
    Stanojevic, S.
    Coriati, A.
    Stephenson, A. L.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
12345